Dying patients get faster access to experimental genetic treatments—if manufacturers agree

What it does

This bill expands the FDA's 'Right to Try' law to allow terminally ill or severely debilitated patients to access experimental treatments tailored to their individual genetic profile (genomic-based drugs) without waiting for full FDA approval, provided their doctor certifies they have exhausted approved options and consent in writing. Manufacturers are not required to provide these treatments but may do so if operating in a certified health care facility.

Why we flagged it

The bill's core function is to extend existing Right to Try protections to a new category of experimental treatments—individualized genomic-based drugs—for terminally ill patients. It is a patient-access measure, not a deregulation or industry carve-out.

What the text implies

• Manufacturers retain absolute discretion to refuse treatment access even if a patient qualifies; the bill creates a right to request, not a right to receive, potentially limiting real-world access.
• The definition of 'investigational individualized medical treatment' is broad (any drug based on genomic analysis) and could encompass treatments at very early stages of development, increasing safety uncertainty.
• No requirement for post-treatment data collection or reporting to FDA; individual access pathways may not generate safety signals that would inform broader regulatory decisions.
• Physicians certifying eligibility face no liability or oversight mechanism if they misrepresent a patient's exhaustion of approved options or prognosis.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with life-threatening or severely debilitating conditions gain a new pathway to potentially life-saving treatments when standard options have failed, with informed consent and physician oversight. The bill does not weaken FDA oversight of approved drugs or clinical trials—it creates a narrow exception for individualized genomic treatments in terminal cases.

Who stands to gain

• genomic medicine companies
• personalized medicine manufacturers
• biotech firms developing individualized treatments

Named in the bill

FDA, Federal Food, Drug, and Cosmetic Act, Section 561B, Public Health Service Act, eligible health care facilities, manufacturers of investigalized individualized medical treatments

Where it stands

3 cosponsors: 3 Republicans.

• Jun 8, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 8, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.